These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22453233)

  • 1. Increased CD133 expression after preoperative chemoradiotherapy in rectal cancers other than mucin-rich tumors.
    Lin CH; Chen WT; Liu CH; Tsai HP; Wu CC; Chai CY
    Virchows Arch; 2012 May; 460(5):447-53. PubMed ID: 22453233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer.
    Yasuda H; Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Kawamoto A; Inoue Y; Miki C; Kusunoki M
    Oncol Rep; 2009 Oct; 22(4):709-17. PubMed ID: 19724847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
    Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
    Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
    Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
    Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy.
    García VM; Batlle JF; Casado E; Burgos E; de Castro J; Belda C; Barriuso J; Sánchez JJ; García-Cabezas MÁ; González-Barón M; Cejas P
    Colorectal Dis; 2011 Sep; 13(9):989-98. PubMed ID: 20718834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Morimoto Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
    Oncol Rep; 2010 Aug; 24(2):345-50. PubMed ID: 20596619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
    Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
    Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
    Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of Smac expression in rectal cancer patients treated with neoadjuvant therapy.
    Yan H; Yu J; Wang R; Jiang S; Zhu K; Mu D; Xu Z
    Med Oncol; 2012 Mar; 29(1):168-73. PubMed ID: 21264534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD133 expression in rectal cancer after preoperative chemoradiotherapy.
    Kojima M; Ishii G; Atsumi N; Nishizawa Y; Saito N; Ochiai A
    Cancer Sci; 2010 Apr; 101(4):906-12. PubMed ID: 20219069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and clinical significance of acellular mucin in locally advanced rectal cancer patients showing pathologic complete response to preoperative chemoradiotherapy.
    Lim SB; Hong SM; Yu CS; Hong YS; Kim TW; Park JH; Kim JH; Kim JC
    Am J Surg Pathol; 2013 Jan; 37(1):47-52. PubMed ID: 23060350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and clinical significance of cellular and acellular mucin in patients with locally advanced mucinous rectal cancer who underwent preoperative chemoradiotherapy followed by radical surgery.
    Kang CM; Lim SB; Hong SM; Yu CS; Hong YS; Kim TW; Park JH; Kim JH; Kim JC
    Colorectal Dis; 2016 Jan; 18(1):O10-6. PubMed ID: 26530997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Koike Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):323-32. PubMed ID: 20970309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Significance of Survivin Expression and Combined Analysis with Cancer Stem Cell and Epithelial-Mesenchymal Transition-related Markers in Patients with Rectal Cancer Undergoing Preoperative Chemoradiotherapy.
    Kim J; Ahn S; Kim K; Cho MS; Kim KH; Lee RA; Nam EM
    Anticancer Res; 2018 Dec; 38(12):6881-6889. PubMed ID: 30504405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
    Yoon G; Lee H; Kim JH; Hur K; Seo AN
    Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD133 expression is an independent prognostic marker for low survival in colorectal cancer.
    Horst D; Kriegl L; Engel J; Kirchner T; Jung A
    Br J Cancer; 2008 Oct; 99(8):1285-9. PubMed ID: 18781171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer.
    Hongo K; Kazama S; Sunami E; Tsuno NH; Takahashi K; Nagawa H; Kitayama J
    Med Oncol; 2012 Dec; 29(4):2849-57. PubMed ID: 22246526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Predictors of Response to Neoadjuvant Chemoradiation for Rectal Cancer.
    Kundel Y; Nasser NJ; Rath-Wolfson L; Purim O; Yanichkin N; Brenner R; Zehavi T; Nardi Y; Fenig E; Sulkes A; Brenner B
    Am J Clin Oncol; 2018 Jun; 41(6):613-618. PubMed ID: 27740975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy.
    Mizukami T; Kamachi H; Mitsuhashi T; Tsuruga Y; Hatanaka Y; Kamiyama T; Matsuno Y; Taketomi A
    BMC Cancer; 2014 Sep; 14():687. PubMed ID: 25240521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy.
    Shia J; McManus M; Guillem JG; Leibold T; Zhou Q; Tang LH; Riedel ER; Weiser MR; Paty PB; Temple LK; Nash G; Kolosov K; Minsky BD; Wong WD; Klimstra DS
    Am J Surg Pathol; 2011 Jan; 35(1):127-34. PubMed ID: 21164296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.